Literature DB >> 12932094

Age-dependent impairment of IgG responses to glycosylphosphatidylinositol with equal exposure to Plasmodium falciparum among Javanese migrants to Papua, Indonesia.

Sarah N Hudson Keenihan1, Sutanti Ratiwayanto, Saraswati Soebianto, Harijani Marwoto, Gowdahalli Krishnegowda, D Channe Gowda, Michael J Bangs, David J Fryauff, Thomas L Richie, Sanjai Kumar, J Kevin Baird.   

Abstract

Immune responses directed at glycosylphosphatidylinositol (GPI) anchors of Plasmodium falciparum may offer protection against symptomatic malaria. To independently explore the effect of age on generation of the anti-GPI IgG response, we measured serum anti-GPI IgGs in a longitudinal cohort of migrant Javanese children (6-12 years old) and adults (> or = 20 years old) with equivalent numbers of exposures to P. falciparum in Papua, Indonesia. While the peak response in adults was achieved after a single infection, comparable responses in children required > or = 3-4 infections. Significantly fewer children (16%) than adults (41%) showed a high (optical density > 0.44) anti-GPI IgG response (odds ratio [OR] = 3.8, 95% confidence interval [CI] = 2.3-6.3, P < 0.0001), and adults were more likely to show a persistently high response (OR = 5.5, 95% CI = 1.0-56.8, P = 0.03). However, the minority of children showing a strong response were significantly less likely to experience symptoms with subsequent parasitemia compared with those with a weak response (OR = 4.0, 95% CI = 1.1-13.8, P = 0.02). This effect was not seen among high- and low-responding adults (OR = 1.2, 95% CI = 0.5-2.8, P = 0.60). Host age, independent of cumulative exposure, apparently represents a key determinant of the quantitative and qualitative nature of the IgG response to P. falciparum GPI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932094

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy controls.

Authors:  Yacouba Cissoko; Modibo Daou; Kirsten E Lyke; Alassane Dicko; Issa Diarra; Abdoulaye Kone; Ando Guindo; Karim Traore; Gowdahalli Krishnegowda; Dapa A Diallo; Ogobara K Doumbo; Christopher V Plowe; D Channe Gowda; Marcelo B Sztein
Journal:  Am J Trop Med Hyg       Date:  2006-08       Impact factor: 2.345

Review 2.  Malaria tolerance--for whom the cell tolls?

Authors:  Craig S Boutlis; Tsin W Yeo; Nicholas M Anstey
Journal:  Trends Parasitol       Date:  2006-06-19

3.  Neutralization of malaria glycosylphosphatidylinositol in vitro by serum IgG from malaria-exposed individuals.

Authors:  J Brian de Souza; Manohursingh Runglall; Patrick H Corran; Lucy C Okell; Sanjeev Kumar; D Channe Gowda; Kevin N Couper; Eleanor M Riley
Journal:  Infect Immun       Date:  2010-06-21       Impact factor: 3.441

4.  Naturally elicited antibodies to glycosylphosphatidylinositols (GPIs) of Plasmodium falciparum require intact GPI structures for binding and are directed primarily against the conserved glycan moiety.

Authors:  Ramachandra S Naik; Gowdahalli Krishnegowda; Christian F Ockenhouse; D Channe Gowda
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

5.  B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon.

Authors:  J C Lima-Junior; J Jiang; R N Rodrigues-da-Silva; D M Banic; T M Tran; R Y Ribeiro; V S E Meyer; S G De-Simone; F Santos; A Moreno; J W Barnwell; M R Galinski; J Oliveira-Ferreira
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

6.  Lack of an association between antibodies to Plasmodium falciparum glycosylphosphatidylinositols and malaria-associated placental changes in Cameroonian women with preterm and full-term deliveries.

Authors:  Amorsolo L Suguitan; D Channe Gowda; Genevieve Fouda; Lucy Thuita; Ainong Zhou; Rosine Djokam; Simon Metenou; Rose G F Leke; Diane Wallace Taylor
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

7.  Cytokine and antibody responses to Plasmodium falciparum in naïve individuals during a first malaria episode: effect of age and malaria exposure.

Authors:  Gemma Moncunill; Alfredo Mayor; Alfons Jiménez; Augusto Nhabomba; Laura Puyol; Maria N Manaca; Diana Barrios; Pau Cisteró; Caterina Guinovart; Ruth Aguilar; Azucena Bardají; María-Jesús Pinazo; Evelina Angov; Sheetij Dutta; Chetan E Chitnis; José Muñoz; Joaquim Gascón; Carlota Dobaño
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

8.  Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity.

Authors:  Josea Rono; Anna Färnert; Linda Murungi; John Ojal; Gathoni Kamuyu; Fatuma Guleid; George Nyangweso; Juliana Wambua; Barnes Kitsao; Ally Olotu; Kevin Marsh; Faith Ha Osier
Journal:  BMC Med       Date:  2015-05-13       Impact factor: 8.775

9.  IgG antibodies to synthetic GPI are biomarkers of immune-status to both Plasmodium falciparum and Plasmodium vivax malaria in young children.

Authors:  Camila T França; Connie S N Li Wai Suen; Amandine Carmagnac; Enmoore Lin; Benson Kiniboro; Peter Siba; Louis Schofield; Ivo Mueller
Journal:  Malar J       Date:  2017-09-25       Impact factor: 2.979

10.  Asymptomatic infection in individuals from the municipality of Barcelos (Brazilian Amazon) is not associated with the anti-Plasmodium falciparum glycosylphosphatidylinositol antibody response.

Authors:  Larissa Rodrigues Gomes; Paulo Renato Rivas Totino; Maria Carmen Arroyo Sanchez; Elsa Paula da Silva Kaingona Daniel; Cristiana Santos de Macedo; Filomeno Fortes; José Rodrigues Coura; Silvia Maria Di Santi; Guilherme Loureiro Werneck; Martha Cecilia Suárez-Mutis; Maria de Fátima Ferreira-da-Cruz; Cláudio Tadeu Daniel-Ribeiro
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-09       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.